

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – November 14, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. October 10, 2012 DUR Minutes – Vote
 - B. October 11, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for October 2012
 - B. Pharmacy Help Desk Activity for October 2012
 - C. Retrospective Drug Evaluation: Focusing on Duplication of Narcotic Therapy

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

5. **Action Item – Vote on 2013 Meeting Dates – See Appendix C.**

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

6. **Action Item – Vote to Update Bladder Control PBPA Category and Prior Authorize Myrbetriq™ – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Update Antidepressants PBPA Category and Prior Authorize Forfivo XL® and Fluoxetine 60mg Tablets – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Miscellaneous Butalbital-Acetaminophen-Caffeine Products – See Appendix F.**
A. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Daliresp® – See Appendix G.**
A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorization Review
D. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Topical Antifungal Medications – See Appendix H.**
A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorization Review
D. Market News and Update
E. COP Recommendations
F. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **30 Day notice to Prior Authorize Relistor® – See Appendix I.**
A. Overview
B. Product Summary
C. COP Recommendations
D. Product Information

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

12. **30 Day notice to Prior Authorize Rayos® – See Appendix J.**
A. Product Summary
B. COP Recommendations
C. Product Information

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**
14. **Future Business**
A. Utilization Review of COPD Medications
B. Annual Reviews
C. New Product Reviews

15. **Adjournment**